Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Janssen is making excellent progress and has recently completed recruitment of 110 patients across two cohorts |
| Conversely, using a fixed dose of levetiracetam with varying doses of ADX71149, levetiracetam increased the potency of 149 leading to an approximate 14 fold shift in its ED50, suggesting a positive pharmacodynamic relationship or strong synergistic effects for the two molecules when given in combination |
| Therefore, we believe that GABAB PAMs could be an innovative new treatment of chronic cough administered once daily via oral dosing and offering improved efficacy and tolerability with fewer non-responder patients suitable for chronic dosing, therefore significantly improving patient quality |
| We believe this can be achieved with positive modulator approach and their differentiated pharmacology having the efficacy of baclofen but longer half-life and improved side effect profile |
| This was encouraging news, suggesting 149 is safe and well-tolerated and potentially offering benefits to epilepsy patients |
| We believe the recommendation of the Independent Review Committee to continue the study is very encouraging and suggests that 149 could be having positive impact on patients |
| And this is why we are very encouraged by the combination of the recommendation to Janssen to continue and the fact that Cohort 2 is a higher dose |
| Therefore, we believe that GABAB PAMs could offer superior efficacy in cough patients |
| Developing mGlu2 NAM offers the exciting opportunity to treat cognitive impairment while also addressing symptoms of depression |
| Exciting new evidence recently published in the Journal Brain suggests that negative allosteric modulator of mGlu5 receptor, MTEP, addressed daily in rats following stroke results in a sustained and growing improvement in sensory motor function in comparison to vehicle treatment |
| This recommendation and the decision of Janssen to continue the study is very encouraging and suggests that 149 is safe and well-tolerated and may be having a positive impact on this patient population |
| ADX71149 has demonstrated both thermal and efficacy and a strong synergistic effect in combination with inhibitors of SV2A such as Keppra and Briviact |
| During Q3, we have continued to advance compounds through clinical candidate selection, multiple compounds showing excellent efficacy and multiple preclinical cough |
| Therefore, I will present this exciting opportunity |
| Our preclinical programs continue to make solid progress towards delivering drug candidates for future clinical development and important therapeutic areas in stress-related disorders, chronic cough, cognition, schizophrenia |
| In summary, our drug discovery engine has made great progress with multiple drug candidates advancing towards IND-enabling studies |
| The renewed commitment of our partner, Indivior and the recent award of a €4 million grant are further validation of the quality and productivity of our allosteric modulation platform |
| We have drug product ready, stroke patent position, and believe Dipraglurant can become a first-in-class drug to facilitate post-stroke recovery |
| We believe the differentiated profile of Dipraglurant makes it particularly suitable for post-stroke recovery |
| We have made great progress in optimizing compounds, identifying highly M4 selective compounds, demonstrating an effect in preclinical models of schizophrenia for several lead compounds and have now entered into clinical candidate selection phase, aiming to identify drug candidates ready to enter IND-enabling studies in 2024 |
| This extraordinary effect of a combination of an mGlu2-PAM with an SV2A antagonist has been patented, offering a strong protection for this program until 2035 without additional extensions |
| There is a strong rationale for developing GABAB PAM for chronic cough |
| On the next slide, we show that GABAB PAMs are likely to have a superior irritability profile in comparison to the current standards of care and show no taste-related side effects, as seen with a newly approved P2X3 inhibitor GABAB PAM |
| There is therefore a strong unmet medical need for better treatment options |
| We have a track record of securing partnerships at the preclinical stage and supported top-tier investors |
| This space is seeing a major breakthrough with the advent of a completely novel approach based on activation of muscarinic M4 acetylcholine receptors |
| The aim of our M4-positive modulation program is to identify highly selective and brain-penetrant molecules, offering potential best-in-class efficacy and tolerability |
| AMPAKines seemed to induce class-related side effects, and we strongly believe our mGlu2 NAM approach will successfully address mNCD without having these side effects |
| However, we are having multiple business discussions across our portfolio and strongly believe that if we are successful in executing our near-term partnering strategy, then our stock price should move to recognize the value of our portfolio |
| We have made substantial progress in our collaboration with our partner Indivior and advancing several novel GABAB compounds coming through your candidate selection |
| Statement |
|---|
| We recognize the 2023 stock performance and current market capitalization is very disappointing |
| However, baclofen has a short half-life and comes with significant side effects hampering its wider use |
| And we have very limited visibility |
| Standard of care antipsychotics as well as non-selective muscarinic agents suffer from significant side effects, leading to high treatment discontinuation rate |
| In addition, the current treatments carry risks of serious side effects |
| Some drugs such as acetylcholinesterase [Ph] inhibitors are being prescribed, but show limited efficacy and come with significant side effects |
| A variety of rehabilitation therapies are used with post-stroke patients, but the recovery is slow and inadequate |
| There is a large unmet medical need in novel antacids drugs as current standards of care are ineffective in 30% of patients and only moderately effective in up to 60% of patients |
| And the fact that they, and also, of course, if they saw any significant safety issues, then they had to recommend stop |
| Schizophrenia affects approximately 1% of the world population, and patients have been treated with the same mechanism of action for the last 50 years with limited efficacy and significant tolerability issues often leading to treatment discontinuation and relapse |
Please consider a small donation if you think this website provides you with relevant information